Genetic testing for mental health can show how your body is likely to process many psychiatric drugs, and the FDA now includes gene information on the labels of several of them. Here is what that means for you, with aripiprazole as a real-world example.
On this page
The FDA labeling of certain mental health medications now includes pharmacogenomic information, because genes can affect how people respond to them. One of the most common medications on this list is Abilify (generic name aripiprazole).
Trial and errors in conventional style medication:
Medications for mental health conditions tend to affect people differently, making the process of finding the right treatment a journey that often involves trial and error. Mental health medications, including antidepressants, antipsychotics, and mood stabilizers, can have varying effects depending on an individual’s unique biology, lifestyle, and other factors. This means that a medication that works well for one person might not have the same positive effect for someone else, and it may even cause unintended side effects.
For example, while some people may experience relief from symptoms with minimal side effects, others may struggle with side effects such as weight gain, fatigue, or emotional numbness.
This unpredictability can lead to a great deal of frustration, and it’s one of the reasons why many individuals hesitate to seek professional help for their mental health. They may be uncertain about whether their doctor will find the right medication for them, or whether the side effects will be manageable. The fear of having to go through multiple adjustments, along with concerns about the impact on their quality of life, can keep people from seeking the help they need.
As a result, the process of trial and error in conventional medication can delay recovery and lead to emotional strain for patients, reinforcing feelings of helplessness.
Introduction to Genetic Testing:
Pharmacogenomics, the study of how genes affect an individual’s response to medications, was invented to help tailor drug prescriptions based on genetic makeup, providing a more personalized and effective approach to treatment. The field of pharmacogenomics emerged in the late 20th century, alongside advancements in genetics and biotechnology, particularly after the completion of the Human Genome Project in 2003. This project allowed researchers to identify the genes responsible for various responses to drugs, leading to breakthroughs in understanding why people react differently to the same medications.
Genetic testing, which is a key component of pharmacogenomics, involves analyzing an individual’s DNA to identify variations that might influence how their body processes and responds to medications. For mental health conditions, genetic tests can help predict how a person may metabolize psychiatric drugs, whether they are at risk for adverse side effects, and which medications may be the most effective. For example, genetic variations can affect how quickly the body breaks down antidepressants, potentially leading to suboptimal dosages if not taken into account.
Genetic testing is increasingly being used in clinical settings to guide medication decisions. For individuals with complex or treatment-resistant mental health conditions, these tests can help reduce the trial-and-error approach that is often associated with conventional medication treatments. Instead of waiting for weeks or months to see how a medication affects them, patients can get a clearer picture of which drugs are more likely to work based on their genetic profile. This can lead to more efficient treatment, fewer side effects, and faster recovery times.
FDA labeling drugs
The FDA (U.S. Food and Drug Administration) includes pharmacogenomic information in the labeling of certain mental health medications, because they may affect individuals differently based on their genetic makeup. These labels are part of the FDA’s ongoing efforts to ensure medications are used as safely and effectively as possible. Some antidepressants (e.g., SSRIs such as citalopram) and antipsychotics (e.g., aripiprazole) are often associated with variability in how they are metabolized by different individuals.
This variability is largely due to genetic differences in drug-metabolizing enzymes, such as CYP2D6 and CYP2C19 from the CYP450 gene family. Lithium is different: it is cleared by the kidneys, not by CYP450 enzymes.
For example, some people may have genetic variations that cause them to metabolize certain drugs too slowly or too quickly, leading to suboptimal effects or unwanted side effects. Others may have genetic variants that make them more sensitive to the drug’s effects, increasing the likelihood of adverse reactions like sedation, dizziness, or even life-threatening conditions like serotonin syndrome. For some of these drugs, the FDA labeling includes pharmacogenomic information, such as dosing advice for known CYP2D6 poor metabolizers, that healthcare providers can consider when prescribing.
By acknowledging the role of genetics in drug efficacy and safety, the FDA is helping to pave the way for more personalized, targeted treatments. This labeling encourages clinicians to consider not only the patient’s symptoms but also their genetic profile when selecting a medication, making it more likely that the chosen treatment is both effective and safe. Genetic testing can thus complement these FDA recommendations, offering valuable insight into a patient’s genetic predispositions and helping to reduce adverse reactions.
These personalized approaches reflect a growing recognition that one-size-fits-all solutions are not always appropriate when it comes to mental health care. Understanding the genetic basis of individual reactions to medications can help improve the efficacy of treatments and reduce the burden of side effects that so many patients experience.
Abilify (commonly known as aripiprazole)
Abilify, also known by its generic name aripiprazole, is one of the most commonly prescribed mental health medications and its FDA label includes dosing guidance for people known to be CYP2D6 poor metabolizers. Abilify is often used to treat conditions such as schizophrenia, bipolar disorder and, as an add-on treatment, major depressive disorder.
The CYP2D6 and CYP3A4 enzymes are mainly responsible for metabolizing Abilify. Individuals who are classified as poor metabolizers of CYP2D6 (meaning they process the drug more slowly) can have higher drug levels on the standard dosage, which may increase side effects. Since poor metabolizers take longer to clear the drug from their system, higher concentrations can build up, increasing the risk of adverse reactions.
As a result, people who are poor metabolizers may need a lower dose of Abilify to avoid these harmful effects. It’s important to recognize that the typical dosage used for the majority of the population may not be appropriate for everyone, and genetic testing can help ensure that individuals receive the safest and most effective dose tailored to their unique genetic profile.
How is Genetic testing helping in mental health medication?
Genetic testing provides valuable insight into how your body is likely to respond to various medications, offering a clearer picture of which drugs are most appropriate for you. By analyzing your DNA, genetic tests can help predict which medications are more likely to be effective and which ones may carry a higher risk of side effects, making the treatment process more personalized and efficient.
One of the benefits of genetic testing is that the DNA report has no expiration date, which means you can get tested now and use the results for years to come. This provides long-term guidance, so even if your medication needs change over time, you’ll have a reliable resource to refer back to. Because your genes do not change, you do not need a new test when your medication regimen changes.
Instead, ask your prescriber or pharmacist to check each new treatment against your existing report, since other drugs you take can also change how these enzymes work.
In the context of mental health treatment, genetic testing can help reduce the trial-and-error process associated with traditional medications, potentially leading to quicker symptom relief and fewer unwanted side effects.
Why get yourself tested from RPh LABS?
RPh LABS, on top of being CLIA-certified and COLA-accredited, provides you with super easy reports that can be easily understood even before visiting a doctor. This report not only tells how your body reacts to different medications but also tells you some of the substitute medications where applicable.
Still, if you or your doctor are unable to read or interpret the PGx / pharmacogenomics report, a PharmD pharmacist reviews every report, and a free pharmacist consultation is included to assist you. Get yourself tested today – treat your mental health with confidence.
References: https://pmc.ncbi.nlm.nih.gov/articles/PMC10675377/#:~:text=4.-,Implementation%20of%20Pharmacogenomics,the%20optimal%20drug%20dosage%20is. https://pubmed.ncbi.nlm.nih.gov/11741220/
What genetic testing for mental health actually checks
Genetic testing for mental health, in the medication sense, is pharmacogenomic testing. It does not look for genes that cause depression, anxiety or schizophrenia. It looks at genes that control how your body absorbs, activates and clears the drugs used to treat them.
The most important genes for psychiatric care are liver enzyme genes. CYP2D6 processes many antidepressants, several antipsychotics and atomoxetine. CYP2C19 processes citalopram, escitalopram and sertraline. CYP2B6 and CYP3A4 add detail for specific drugs.
The sample is a quick cheek swab. The lab reads the known variants in each gene and assigns a metabolizer status, from poor to ultrarapid. Your report then lists medications with a plain flag, such as standard use or use with caution, so you and your prescriber can see where your genes matter.
For a broader introduction, see our guide to what PGx testing is or the NHGRI glossary entry on pharmacogenomics.
How to read an fda drug label for gene information
Every prescription drug sold in the US has an official prescribing information document, often called the label. When a gene affects how a drug works, the FDA drug label may mention it in sections such as Dosage and Administration, Warnings and Precautions, Use in Specific Populations or Clinical Pharmacology.
Gene information on a label comes in different strengths. Some labels give a clear dose change for a known genotype. Others only describe that drug levels differ by genotype. A small number carry a boxed warning or recommend testing before treatment.
A key psychiatric example of that last group is carbamazepine. Its label warns about serious skin reactions in people who carry HLA-B*15:02, a variant most common in people with Asian ancestry, and recommends screening at-risk patients before starting.
You do not need to read labels yourself. The FDA keeps a searchable table of pharmacogenomic biomarkers in drug labeling, and your pharmacist can explain what a given FDA drug label says about your result.
Aripiprazole cyp2d6 dosing in plain terms
Aripiprazole (Abilify) is used for schizophrenia, bipolar disorder and, as an add-on, for major depressive disorder. CYP2D6 and CYP3A4 are the main enzymes that clear it from the body.
The aripiprazole CYP2D6 guidance on the FDA label is specific. For people known to be CYP2D6 poor metabolizers, the label advises giving half the usual dose. If a poor metabolizer also takes a strong CYP3A4 inhibitor, the label advises a further reduction.
The same aripiprazole CYP2D6 logic applies when a strong CYP2D6 blocker is added. Fluoxetine and paroxetine, both common antidepressants, can push aripiprazole levels up, and the label addresses that combination too. This is why your prescriber needs both your genetic report and your full medication list.
Brexpiprazole (Rexulti), a related drug, has a similar FDA drug label section for CYP2D6. Any dose change is your prescriber’s decision. Do not adjust aripiprazole or any other psychiatric medicine on your own, even if your report flags it.
Life as a cyp2d6 poor metabolizer
Being a CYP2D6 poor metabolizer means the enzyme has little or no activity. It is inherited, it is not a disease and it does not cause symptoms on its own. It matters only when you take a drug that depends on CYP2D6.
For drugs that CYP2D6 clears, levels can build up in a CYP2D6 poor metabolizer. Psychiatric examples, each with gene guidance on its FDA drug label or in CPIC guidelines, include:
- Atomoxetine: the label advises a slower dose increase for poor metabolizers.
- Vortioxetine: the label sets a lower maximum dose for known poor metabolizers.
- Paroxetine and some tricyclics: CPIC guidelines suggest dose changes or alternatives.
- Pimozide and iloperidone: labels include CYP2D6 dosing limits.
The opposite happens with drugs that CYP2D6 activates. Codeine and tramadol need CYP2D6 to become active, so a CYP2D6 poor metabolizer may get little pain relief from them. That is a good reason to share your report beyond your psychiatrist. Our medication list shows 263 medications by gene.
Psychiatric medication side effects and where genes fit
Psychiatric medication side effects fall into a few groups, and genes help with some more than others. Genetic testing for mental health is most useful for the first group below.
- Dose-related effects: nausea, sedation, dizziness or restlessness that grow with drug level. Metabolizer status is most useful here.
- Rare but serious reactions: such as severe skin reactions to carbamazepine linked to HLA-B*15:02. HLA screening is a separate test and is not part of every PGx panel, including the RPh Labs panel.
- Effects not well predicted by genes: weight gain, sexual side effects and emotional blunting depend on many factors and are not reliably predicted by current tests.
- Interaction effects: combining drugs that raise serotonin can cause serotonin syndrome regardless of genotype.
Knowing which group your psychiatric medication side effects fall into helps set realistic goals. A report can help your prescriber avoid a starting dose that is likely too high for you. It cannot promise a side effect-free experience.
If you are having psychiatric medication side effects now, call your prescriber or pharmacist. Some effects fade in the first weeks, others need a change, and a few need urgent care.
Steps before and after genetic testing for mental health
A little planning makes genetic testing for mental health easier to use. Before you swab, and after results arrive, work through these steps.
- Write down every psychiatric medicine you have tried, the dose and why it stopped, such as no benefit or psychiatric medication side effects.
- Add all current medicines, supplements and over-the-counter drugs.
- Complete the cheek swab as described in the kit and mail it back.
- When results arrive, read the summary page and note any drug flagged as use with caution or consider alternatives.
- Book time with your prescriber to review the report. Ask how it applies to your current treatment and future options.
Your history of past reactions is valuable context. A drug that caused strong side effects in the past, combined with a CYP2D6 poor metabolizer result, gives your prescriber a clearer story than either fact alone.
Prescribers who want to learn more can find resources on our for providers page.
Keeping your results useful for years
Genetic testing for mental health only needs to be done once. The genes on a PGx report are inherited, so your genotype does not change during your life. You do not need to repeat the DNA test when your medication changes.
Two things do change. First, the science. Groups such as CPIC update their guidelines as new evidence arrives, and an FDA drug label can be revised. RPh Labs updates reports when guidelines change. Second, your medication list. New drugs can block or boost enzymes, which changes how your genes play out in real life.
To get the most from one test, keep a copy of your report with your medical records and share it with every prescriber and pharmacy you use. Ask your pharmacist to check it whenever a new medicine is started.
Cost and insurance for testing with RPh Labs
The RPh Labs at-home PGx kit costs $299 self-pay, is HSA and FSA eligible and can be split into four interest-free installments. Shipping is free both ways, and kits ship within one business day.
Our CLIA-certified, COLA-accredited lab in Dallas, Texas tests 20 genes, including CYP2D6, CYP2C19, CYP2B6 and CYP3A4, and reports on more than 240 medications. Results arrive 7 to 10 business days after your sample reaches the lab. A PharmD pharmacist reviews every report, and a free consultation is included.
We accept insurance including Medicare, Texas Medicaid (TMHP) and Blue Cross Blue Shield of Texas. Check your plan on our insurance page or call (888) 383-2181.
Genetic testing for mental health FAQ
Does the FDA require a gene test before taking aripiprazole?
No. The aripiprazole label does not require testing. It gives dosing advice for people already known to be CYP2D6 poor metabolizers, which is why having results on file can help. Your prescriber decides whether testing makes sense for you before or during treatment.
What does aripiprazole CYP2D6 guidance mean if I already take it?
If you already take aripiprazole and feel well, a poor metabolizer result is not a reason to stop. Share the report with your prescriber, who can check whether your dose fits the label advice and your response so far. Never change the dose yourself.
Can a gene test predict weight gain from psychiatric drugs?
Not reliably. Weight gain with some antipsychotics and antidepressants depends on the drug, dose, diet, activity and many genes with small effects. Current PGx panels focus on how drugs are processed, which helps more with dose-related side effects than with weight change.
Which drugs besides psychiatric ones can a CYP2D6 poor metabolizer react to?
CYP2D6 also affects some pain medicines, heart drugs and anti-nausea drugs. Codeine and tramadol are well-known examples, since they need CYP2D6 to become active. That is why it helps to share your report with every prescriber, not only your psychiatrist.
Is genetic testing for mental health covered by insurance?
Some plans cover it when a prescriber documents a medical need. RPh Labs accepts insurance including Medicare, Texas Medicaid (TMHP) and Blue Cross Blue Shield of Texas. Self-pay is $299 and is HSA and FSA eligible.
Leave a Reply